Effects of resveratrol on the acquisition and reinstatement of morphine‑induced conditioned place preference in mice

Rezaee,Ramin; Jangjoo,Saeedeh; Ekhtiary,Sarvenaz; Anani,Mohammad  Amir; Tsatsakis,Aristidis; Spandidos,Demetrios  A.; Nepka,Charitini; Hashemzaei,Mahmoud

doi:10.3892/wasj.2020.38

Effects of resveratrol on the acquisition and reinstatement of morphine‑induced conditioned place preference in mice

Authors:
- Ramin Rezaee
- Saeedeh Jangjoo
- Sarvenaz Ekhtiary
- Mohammad Amir Anani
- Aristidis Tsatsakis
- Demetrios A. Spandidos
- Charitini Nepka
- Mahmoud Hashemzaei
View Affiliations

Affiliations: Clinical Research Unit, Faculty of Medicine, Mashhad University of Medical Sciences, 913753316 Mashhad, Iran, Students Research Committee, School of Pharmacy, Zabol University of Medical Sciences, 9861615881 Zabol, Iran, Laboratory of Toxicology Science and Research, Medical School, University of Crete, 71003 Heraklion, Greece, Department of Virology, Medical School, University of Crete, 71003 Heraklion, Greece, Department of Pathology and Cytology, University Hospital of Larissa, 41110 Larissa, Greece
Published online on: February 17, 2020 https://doi.org/10.3892/wasj.2020.38
Pages: 77-82
Copyright: © Rezaee et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Seeking opioids, even after a prolonged withdrawal period, is a main concern of opioid withdrawal. Resveratrol (RES) has been shown to exert inhibitory effects on glutamate release from cerebrocortical nerve terminals via N‑methyl‑D‑aspartate (NMDA) antagonistic effects. In this study, the effects of RES on the acquisition and reinstatement of morphine were examined in a mouse model using the morphine‑induced conditioned place preference (CPP) paradigm. In the first step, namely the acquisition phase, morphine was administered to mice for 4 consecutive days (daily 40 mg/kg, i.p. injection) and the mice were trained in a CPP chamber. In the second step, namely extinction and reinstatement, the animals underwent the same CPP training followed by extinction training on day 16 and reinstatement was investigated by CPP following the administration of a ‘reminding’ dose of morphine (10 mg/kg). Finally, the effects of RES (25, 50 and 75 mg/kg) on the acquisition and reinstatement induced by morphine were examined in a CPP test. Based on our data, RES (25, 50 and 75 mg/kg) reduced morphine tendency. In the second step of the experiment, after day 16 (following the ‘reminder’ dose of morphine at 10 mg/kg), the tendency of the animals for the white, drug‑paired compartment of the CPP chamber significantly decreased following treatment with RES at 50 and 75 mg/kg (but not at 25 mg/kg). On the whole, the findings of this study demonstrate that RES decreases the acquisition and reinstatement of morphine‑induced CPP in mice.

View Figures

View References

1	Kest B, McLemore G, Kao B and Inturrisi CE: The competitive α-amino-3-hydroxy-5-methylisoxazole-4-propionate receptor antagonist LY293558 attenuates and reverses analgesic tolerance to morphine but not to delta or kappa opioids. J Pharmacol Exp Ther. 283:1249–1255. 1997.PubMed/NCBI
2	Mayer DJ, Mao J, Holt J and Price DD: Cellular mechanisms of neuropathic pain, morphine tolerance, and their interactions. Proc Natl Acad Sci USA. 96:7731–7736. 1999.PubMed/NCBI View Article : Google Scholar
3	Tsatsakis A, Docea AO, Calina D, Tsarouhas K, Zamfira LM, Mitrut R, Sharifi-Rad J, Kovatsi L, Siokas V, Dardiotis E, et al: A Mechanistic and Pathophysiological Approach for Stroke Associated with Drugs of Abuse. J Clin Med. 8(1295)2019.PubMed/NCBI View Article : Google Scholar
4	Kratzer U and Schmidt WJ: The anti-craving drug acamprosate inhibits the conditioned place aversion induced by naloxone-precipitated morphine withdrawal in rats. Neurosci Lett. 252:53–56. 1998.PubMed/NCBI View Article : Google Scholar
5	Theberge FR, Li X, Kambhampati S, Pickens CL, St Laurent R, Bossert JM, Baumann MH, Hutchinson MR, Rice KC, Watkins LR, et al: Effect of chronic delivery of the Toll-like receptor 4 antagonist (+)-naltrexone on incubation of heroin craving. Biol Psychiatry. 73:729–737. 2013.PubMed/NCBI View Article : Google Scholar
6	Dhawan K, Kumar S and Sharma A: Reversal of Morphine Tolerance and Dependence by Passiflora incarnata - A Traditional Medicine to Combat Morphine Addiction. Pharm Biol. 40:576–580. 2002.
7	Tabatabai SM, Dashti S, Doosti F and Hosseinzadeh H: Phytotherapy of opioid dependence and withdrawal syndrome: A review. Phytother Res. 28:811–830. 2014.PubMed/NCBI View Article : Google Scholar
8	Ribeiro Do Couto B, Aguilar MA, Manzanedo C, Rodríguez-Arias M and Miñarro J: Effects of NMDA receptor antagonists (MK-801 and memantine) on the acquisition of morphine-induced conditioned place preference in mice. Prog Neuropsychopharmacol Biol Psychiatry. 28:1035–1043. 2004.PubMed/NCBI View Article : Google Scholar
9	Guo SJ, Cui Y, Huang ZZ, Liu H, Zhang XQ, Jiang JX and Xin WJ: Orexin A-mediated AKT signaling in the dentate gyrus contributes to the acquisition, expression and reinstatement of morphine-induced conditioned place preference. Addict Biol. 21:547–559. 2016.PubMed/NCBI View Article : Google Scholar
10	Al-Harthi SE, Alarabi OM, Ramadan WS, Alaama MN, Al-Kreathy HM, Damanhouri ZA, Khan LM and Osman AM: Amelioration of doxorubicin induced cardiotoxicity by resveratrol. Mol Med Rep. 10:1455–1460. 2014.PubMed/NCBI View Article : Google Scholar
11	Hamza RZ and El-Shenawy NS: Anti-inflammatory and antioxidant role of resveratrol on nicotine-induced lung changes in male rats. Toxicol Rep. 4:399–407. 2017.PubMed/NCBI View Article : Google Scholar
12	Theodotou M, Fokianos K, Moniatis D, Kadlenic R, Chrysikou A, Aristotelous A, Mouzouridou A, Diakides J and Stavrou E: Effect of resveratrol on non-alcoholic fatty liver disease. Exp Ther Med. 18:559–565. 2019.PubMed/NCBI View Article : Google Scholar
13	Goutzourelas N, Stagos D, Spanidis Y, Liosi M, Apostolou A, Priftis A, Haroutounian S, Spandidos DA, Tsatsakis AM and Kouretas D: Polyphenolic composition of grape stem extracts affects antioxidant activity in endothelial and muscle cells. Mol Med Rep. 12:5846–5856. 2015.PubMed/NCBI View Article : Google Scholar
14	Hashemzaei M, Barani AK, Iranshahi M, Rezaee R, Tsarouhas K, Tsatsakis AM, Wilks MF and Tabrizian K: Effects of resveratrol on carbon monoxide-induced cardiotoxicity in rats. Environ Toxicol Pharmacol. 46:110–115. 2016.PubMed/NCBI View Article : Google Scholar
15	Hashemzaei M, Karami SP, Delaramifar A, Sheidary A, Tabrizian K, Rezaee R, Shahsavand S, Arsene AL, Tsatsakis AM and Taghdisi SM: Anticancer effects of co-administration of daunorubicin and resveratrol in MOLT-4, U266 B1 and RAJI cell lines. Farmacia. 64:36–42. 2016.
16	Labinskyy N, Csiszar A, Veress G, Stef G, Pacher P, Oroszi G, Wu J and Ungvari Z: Vascular dysfunction in aging: Potential effects of resveratrol, an anti-inflammatory phytoestrogen. Curr Med Chem. 13:989–996. 2006.PubMed/NCBI View Article : Google Scholar
17	Russo GL: Ins and outs of dietary phytochemicals in cancer chemoprevention. Biochem Pharmacol. 74:533–544. 2007.PubMed/NCBI View Article : Google Scholar
18	Tabrizian K, Musavi SS, Rigi M, Hosseindadi F, Kordi S, Shamshirgaran F, Bazi A, Shahraki J, Rezaee R and Hashemzaei M: Behavioral and molecular effects of intrahippocampal infusion of auraptene, resveratrol, and curcumin on H-89-induced deficits on spatial memory acquisition and retention in Morris water maze. Hum Exp Toxicol. 38:775–784. 2019.PubMed/NCBI View Article : Google Scholar
19	Tabrizian K, Shahraki J, Bazzi M, Rezaee R, Jahantigh H and Hashemzaei M: Neuro-Protective Effects of Resveratrol on Carbon Monoxide-Induced Toxicity in Male Rats. Phytother Res. 31:1310–1315. 2017.PubMed/NCBI View Article : Google Scholar
20	Zhao YN, Li WF, Li F, Zhang Z, Dai YD, Xu AL, Qi C, Gao JM and Gao J: Resveratrol improves learning and memory in normally aged mice through microRNA-CREB pathway. Biochem Biophys Res Commun. 435:597–602. 2013.PubMed/NCBI View Article : Google Scholar
21	Ghazanfarpour M, Najafi MN, Roozbeh N, Mashhadi ME, Keramat-Roudi A, Mégarbane B, Tsatsakis A, Moghaddam MMM and Rezaee R: Therapeutic approaches for neonatal abstinence syndrome: A systematic review of randomized clinical trials. Daru. 27:423–431. 2019.PubMed/NCBI View Article : Google Scholar
22	Gentilli M, Mazoit JX, Bouaziz H, Fletcher D, Casper RF, Benhamou D and Savouret JF: Resveratrol decreases hyperalgesia induced by carrageenan in the rat hind paw. Life Sci. 68:1317–1321. 2001.PubMed/NCBI View Article : Google Scholar
23	Tsai RY, Chou KY, Shen CH, Chien CC, Tsai WY, Huang YN, Tao PL, Lin YS and Wong CS: Resveratrol regulates N-methyl-D-aspartate receptor expression and suppresses neuroinflammation in morphine-tolerant rats. Anesth Analg. 115:944–952. 2012.PubMed/NCBI View Article : Google Scholar
24	Shen CH, Tsai RY, Tai YH, Lin SL, Chien CC and Wong CS: Intrathecal etanercept partially restores morphine's antinociception in morphine-tolerant rats via attenuation of the glutamatergic transmission. Anesth Analg. 113:184–190. 2011.PubMed/NCBI View Article : Google Scholar
25	Schmatz R, Mazzanti CM, Spanevello R, Stefanello N, Gutierres J, Corrêa M, da Rosa MM, Rubin MA, Chitolina Schetinger MR and Morsch VM: Resveratrol prevents memory deficits and the increase in acetylcholinesterase activity in streptozotocin-induced diabetic rats. Eur J Pharmacol. 610:42–48. 2009.PubMed/NCBI View Article : Google Scholar
26	Marambaud P, Zhao H and Davies P: Resveratrol promotes clearance of Alzheimer's disease amyloid-β peptides. J Biol Chem. 280:37377–37382. 2005.PubMed/NCBI View Article : Google Scholar
27	MacCarrone M, Lorenzon T, Guerrieri P and Agrò AF: Resveratrol prevents apoptosis in K562 cells by inhibiting lipoxygenase and cyclooxygenase activity. Eur J Biochem. 265:27–34. 1999.PubMed/NCBI View Article : Google Scholar
28	Subbaramaiah K, Chung WJ, Michaluart P, Telang N, Tanabe T, Inoue H, Jang M, Pezzuto JM and Dannenberg AJ: Resveratrol inhibits cyclooxygenase-2 transcription and activity in phorbol ester-treated human mammary epithelial cells. J Biol Chem. 273:21875–21882. 1998.PubMed/NCBI View Article : Google Scholar
29	Subbaramaiah K, Michaluart P, Chung WJ, Tanabe T, Telang N and Dannenberg AJ: Resveratrol inhibits cyclooxygenase-2 transcription in human mammary epithelial cells. Ann N Y Acad Sci. 889:214–223. 1999.PubMed/NCBI View Article : Google Scholar
30	Pérez-Severiano F, Bermúdez-Ocaña DY, López-Sánchez P, Ríos C and Granados-Soto V: Spinal nerve ligation reduces nitric oxide synthase activity and expression: Effect of resveratrol. Pharmacol Biochem Behav. 90:742–747. 2008.PubMed/NCBI View Article : Google Scholar
31	Imenshahidi M, Qaredashi R, Hashemzaei M and Hosseinzadeh H: Inhibitory Effect of Berberis vulgaris Aqueous Extract on Acquisition and Reinstatement Effects of Morphine in Conditioned Place Preferences (CPP) in Mice. Jundishapur J Nat Pharm Prod. 9(e16145)2014.PubMed/NCBI View Article : Google Scholar
32	Qaredashi R, Hosseinzadeh H and Hashemzaei M: Inhibitory effect of Berberis vulgaris aqueous extract on acquisition and reinstatement effects of morphine in conditioned place preferences (CPP) in mice. Res Pharm Sci. 7(S839)2012.
33	Gao ZB, Chen XQ and Hu GY: Inhibition of excitatory synaptic transmission by trans-resveratrol in rat hippocampus. Brain Res. 1111:41–47. 2006.PubMed/NCBI View Article : Google Scholar
34	Chang Y and Wang SJ: Inhibitory effect of glutamate release from rat cerebrocortical nerve terminals by resveratrol. Neurochem Int. 54:135–141. 2009.PubMed/NCBI View Article : Google Scholar